Unit
- Clear cell RCC: The most common subtype, accounting for approximately 75% of cases, originates from proximal tubular epithelial cells and is characterized by loss of the von Hippel-Lindau tumor suppressor gene leading to hypoxia-inducible factor accumulation and angiogenic pathway activation.
- Papillary RCC: Representing 15-20% of kidney cancers, this subtype features papillary growth patterns and is further divided into type 1 (often associated with MET pathway mutations) and type 2 (linked to fumarate hydratase deficiency and more aggressive behavior).
- Chromophobe RCC: A less common variant (5%) arising from intercalated cells of the collecting duct, typically with a better prognosis, characterized by large polygonal cells with perinuclear halos and frequent chromosomal losses.
- Collecting duct carcinoma: A rare and aggressive subtype originating from the medullary collecting ducts, often presenting with advanced disease and showing mixed tubular and papillary architecture with a desmoplastic stromal reaction.
- Oncocytoma: A benign renal tumor composed of oncocytes (eosinophilic cells with abundant mitochondria), often difficult to distinguish from RCC on imaging but lacking malignant potential and requiring no treatment beyond diagnosis.
- Sarcomatoid differentiation: Not a distinct subtype but a dedifferentiated pattern that can occur in any RCC subtype, characterized by spindle cell morphology and associated with rapid progression, higher metastatic risk, and poorer response to conventional therapies.
- Molecular pathogenesis: The VHL/HIF pathway is central in clear cell RCC, while papillary RCC involves MET, C-MYC, and NRF2 pathway alterations; chromophobe RCC is linked to mitochondrial DNA mutations and TP53 changes; understanding these pathways guides targeted therapy selection.
- Epidemiological trends: Kidney cancer incidence has been rising globally, partly due to increased incidental detection through cross-sectional imaging, with higher rates in males, older age groups, and populations with obesity, hypertension, and smoking history; survival has improved with modern therapies.
Terminology
- Clear cell RCC
- Characterized by clear cytoplasm due to lipid and glycogen accumulation; most common kidney cancer subtype.
- von Hippel-Lindau (VHL) gene
- Tumor suppressor gene frequently inactivated in clear cell RCC, leading to HIF accumulation and angiogenesis.
- Papillary RCC
- Kidney cancer subtype with papillary architecture; divided into type 1 and type 2 with distinct genetic profiles.
- Chromophobe RCC
- Less aggressive subtype with large polygonal cells and perinuclear halos; better prognosis than clear cell or papillary RCC.
Quick Revision
- Clear cell RCC is the most common subtype, driven by VHL inactivation and HIF pathway activation.
- Papillary RCC accounts for 15-20% and is associated with MET mutations in type 1.
- Chromophobe RCC has a favorable prognosis and distinct histologic features.
- Collecting duct carcinoma and sarcomatoid differentiation are aggressive variants.
- Molecular understanding of subtypes guides treatment selection in systemic therapy.